Antimicrobial activity of DC-159a, a new fluoroquinolone, against 1,149 recently collected clinical isolates.
The activity of DC-159a, a novel orally administered fluorinated quinolone, was evaluated by reference broth microdilution or agar dilution methods against 1,149 recently collected clinical isolates from five continents. Against pathogens associated with community-acquired respiratory tract infections (CA-RTIs), the MIC(90)s were 0.12 microg/ml for Streptococcus pneumoniae, 0.015 to 0.03 microg/ml for Haemophilus influenzae, 0.03 microg/ml for Moraxella catarrhalis, and 0.12 microg/ml for beta-hemolytic streptococci. Similarly, DC-159a was potent against various types of staphylococci (MIC(90) range, 0.03 to 2 microg/ml), Enterococcus faecalis (MIC(90), 4 microg/ml), wild-type isolates of the family Enterobacteriaceae (MIC(90) range, 0.06 to 2 microg/ml), wild-type Pseudomonas aeruginosa (MIC(90), 2 microg/ml), and Acinetobacter spp. (MIC(90), 0.12 microg/ml). Fluoroquinolone-nonsusceptible organism subsets usually had elevated DC-159a MICs, but the MICs were often two- to fourfold lower than those of levofloxacin and moxifloxacin. In conclusion, DC-159a appears to possess a balanced broad spectrum of activity that exceeds the activities of the currently marketed fluoroquinolones, especially against pathogens that cause CA-RTIs.
JMI Laboratories, 345 Beaver Kreek Center, North Liberty, IA 52317, USA. ronald-jones@jmilabs.com
Ronald N
RN
Jones
Thomas R
TR
Fritsche
Helio S
HS
Sader
D000150:Acinetobacter / Q000187:drug effects / Q000302:isolation & purification; D000631:Aminopyridines / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D024881:Drug Resistance, Bacterial; D004755:Enterobacteriaceae / Q000187:drug effects / Q000302:isolation & purification; D013293:Enterococcus faecalis / Q000187:drug effects / Q000302:isolation & purification; D024841:Fluoroquinolones / Q000494:pharmacology*; D006193:Haemophilus influenzae / Q000187:drug effects / Q000302:isolation & purification; D006801:Humans; D008089:Listeria monocytogenes / Q000187:drug effects / Q000302:isolation & purification; D008826:Microbial Sensitivity Tests; D001936:Moraxella catarrhalis / Q000187:drug effects / Q000302:isolation & purification; D009344:Neisseria gonorrhoeae / Q000187:drug effects / Q000302:isolation & purification; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000302:isolation & purification; D013210:Staphylococcus / Q000187:drug effects / Q000302:isolation & purification; D013291:Streptococcus / Q000187:drug effects / Q000302:isolation & purification; D013296:Streptococcus pneumoniae / Q000187:drug effects / Q000302:isolation & purification
C530475:7-(7-amino-7-methyl-5-azaspiro(2.4)heptan-5-yl)-6-fluoro-1-(2-fluoro-1-cyclopropyl)-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid; D000631:Aminopyridines; D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones